Abbott
Closed portfolio snapshot
According to ClinicalTrials.gov-derived indexes, Abbott sits in the top decile of US sponsors by registered trial count (#166 of 15,742 sponsors by registered trial count).
Abbott: 181 sponsored US clinical trials, none currently recruiting.
Abbott sponsors 181 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 158 completed. 90 of these trials are in Phase 3-4 (later-stage) and 83 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 7 trials.
Top-decile sponsor footprint
Abbott ranks in the top decile of sponsors by registered trial count (#166 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
158 of 181 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (87.3%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Indexed trials (enrollment closed)
181 total, page 4 of 4
Study of Lopinavir, Ritonavir, Tenofovir and Emtricitabine in HIV-Infected Antiretroviral Naïve Subjects
NCT00043966
Safety and Efficacy of Atrasentan in Men With Hormone Naive Prostate Cancer Exhibiting Early Signs of Biochemical Failure
NCT00038662
A Study of the Human Anti-TNF Antibody Adalimumab for the Induction of Clinical Remission in Subjects With Crohn's Disease
NCT00055523
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Daily Dosing)
NCT00048516
Safety and Efficacy of Zemplar Capsule in Reducing Serum IPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
NCT00048438
Safety and Efficacy of Zemplar Capsule in Reducing Serum iPTH Levels in Chronic Kidney Disease Subjects (Three Times Weekly)
NCT00048451
A Study to Evaluate the Safety and Efficacy of Paricalcitol Capsules in Reducing Serum Intact Parathyroid Hormone Levels in End Stage Renal Disease Subjects on Peritoneal Dialysis
NCT00646035
Safety and Effectiveness of Zemplar Injection in Decreasing iPTH Levels in Pediatric ESRD Subjects on Hemodialysis
NCT00053547
A Study to Examine the Use of Zemplar to Increase Serum Calcium Levels in ICU Subjects
NCT00053378
A Long Term Safety Study With Atrasentan
NCT00127478
Study of Atrasentan in Men With Non-Metastatic, Hormone-Refractory Prostate Cancer
NCT00036556
A Study of Atrasentan in Men With Metastatic, Hormone-Refractory Prostate Cancer
NCT00036543
Amprenavir/Ritonavir or Saquinavir/Ritonavir in HIV-Infected Subjects Following Failure With Kaletra as Their Second Protease Inhibitor
NCT00038519
Amprenavir/Ritonavir, Saquinavir/Ritonavir or Efavirenz in HIV-Infected Subjects Following Failure With Kaletra (ABT-378/Ritonavir) as Their First Protease Inhibitor Based HAART
NCT00038532
A Study of Two Different Doses of ABT-378/Ritonavir in HIV-Infected Patients Who Have Taken Protease Inhibitors and Non-Nucleoside Reverse Transcriptase Inhibitors
NCT00038636
Long Term Open Label Continuation Study
NCT00195650
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected Patients
NCT00038220
Efficacy and Safety of Adalimumab in Patients With Active Rheumatoid Arthritis Treated Concomitantly With Methotrexate.
NCT00195702
A Phase III Study Comparing Two Different Anti-HIV Drug Combinations in HIV-Positive Patients Without Previous Anti-HIV Drug Therapy
NCT00004583
ABT-378/Ritonavir in Combination With Reverse Transcriptase Inhibitors in Antiretroviral Naïve HIV-Infected Subjects
NCT00004578
The Safety and Effectiveness of Clarithromycin Plus Ethambutol Used With or Without Clofazimine in the Treatment of MAC in Patients With AIDS
NCT00002331
The Safety and Effectiveness of Clarithromycin in the Prevention of Mycobacterium Avium Complex (MAC) Infection in HIV-Infected Patients
NCT00002336
Study of Lupron Depot In The Treatment of Central Precocious Puberty
NCT00660010
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
NCT00004581
The Safety and Effectiveness of Clarithromycin Plus Zidovudine or Dideoxyinosine in the Treatment of Mycobacterium Avium Complex (MAC) Infections in Children With AIDS
NCT00000971
A Study of ABT-378/Ritonavir Combination in HIV-Infected Patients Who Have Taken Protease Inhibitors
NCT00004580
A Study of Ritonavir (ABT-538) When Used With Nelfinavir in HIV-Infected Patients
NCT00002201
Phase I Safety Study of Anti-HIV Immune Serum Globulin (Human)
NCT00002036
A Study of Ritonavir/Indinavir Combination in HIV-Infected Patients
NCT00002223
A Comparison of Two Types of Injected Nutritional Supplements in Patients With AIDS and Pneumocystis Carinii Pneumonia (PCP)
NCT00002275
Long-Term Nutritional Support in Patients With the Acquired Immunodeficiency Syndrome: Comparison of Liposyn III 2 Percent With Liposyn II 20 Percent
NCT00002029
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 46 |
| Phase 2 | 37 |
| Phase 3 | 71 |
| Phase 4 | 19 |
How the Abbott archive is shaped
181 indexed studies, none listed as recruiting (0% open); 158 completed (87%).
Phase mix: 90 late (III/IV) vs 83 early (I/II) (balanced across stages).
Top condition: Healthy (7 trials), 9 others listed.
How to read a closed sponsor archive
When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.
Abbott: archived-pipeline peers nationwide
Peers matched on 181 indexed studies with no current recruiting: volume and archive shape, not condition overlap.
Abbott sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 181 archived trials
- ViiV Healthcare · 182 trials · 4% recruiting
- Baylor Research Institute · 180 trials · 17% recruiting
- Fox Chase Cancer Center · 183 trials · 16% recruiting
- Children's Mercy Hospital Kansas City · 184 trials · 11% recruiting
Sponsors with similar archive density (± trial count)
- 10xBio · 0% recruiting · 3 trials
- 22nd Century Group · 0% recruiting · 3 trials
- 23andMe · 0% recruiting · 6 trials
- 3-C Institute for Social Development · 0% recruiting · 14 trials
Related
What to do with this Abbott page
181 registered trials is a research-attention snapshot, not an endorsement of Abbott or any single study.
- None of Abbott's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
- Healthy is the condition Abbott studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Abbott pipeline card: 181 registered trials from official public datasets.Report a data error.